Fmr LLC Lowers Stake in Glaukos Corp (NYSE:GKOS)

FMR LLC reduced its stake in shares of Glaukos Corp (NYSE:GKOS) by 22.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,778,297 shares of the medical instruments supplier’s stock after selling 501,881 shares during the quarter. FMR LLC owned approximately 4.89% of Glaukos worth $139,365,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of GKOS. Meeder Asset Management Inc. purchased a new stake in shares of Glaukos during the first quarter worth about $48,000. Marshall Wace North America L.P. purchased a new stake in Glaukos in the first quarter valued at approximately $55,000. NumerixS Investment Technologies Inc boosted its position in Glaukos by 20.7% in the fourth quarter. NumerixS Investment Technologies Inc now owns 1,100 shares of the medical instruments supplier’s stock valued at $61,000 after buying an additional 189 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in Glaukos by 251.7% in the first quarter. Oppenheimer Asset Management Inc. now owns 1,938 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 1,387 shares during the last quarter. Finally, Advisor Group Inc. boosted its position in Glaukos by 97.6% in the fourth quarter. Advisor Group Inc. now owns 3,439 shares of the medical instruments supplier’s stock valued at $192,000 after buying an additional 1,699 shares during the last quarter. 95.74% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have commented on GKOS shares. Wells Fargo & Co restated a “buy” rating on shares of Glaukos in a research report on Wednesday, March 20th. BTIG Research restated a “hold” rating on shares of Glaukos in a research report on Wednesday, May 22nd. Zacks Investment Research lowered German American Bancorp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Finally, BMO Capital Markets upped their price objective on goeasy from C$55.00 to C$60.00 in a research report on Thursday, May 9th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Glaukos currently has a consensus rating of “Buy” and a consensus target price of $72.56.

NYSE GKOS traded down $0.51 during mid-day trading on Thursday, hitting $76.24. The stock had a trading volume of 332,857 shares, compared to its average volume of 379,331. Glaukos Corp has a twelve month low of $36.89 and a twelve month high of $83.14. The company has a market capitalization of $2.80 billion, a PE ratio of -206.05 and a beta of 1.61. The stock’s 50 day moving average is $73.68. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.72 and a quick ratio of 6.23.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. Glaukos had a negative return on equity of 6.90% and a negative net margin of 5.93%. The business had revenue of $54.03 million during the quarter, compared to the consensus estimate of $50.13 million. On average, sell-side analysts anticipate that Glaukos Corp will post -0.3 earnings per share for the current year.

In other Glaukos news, CFO Joseph E. Gilliam sold 2,603 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $65.14, for a total value of $169,559.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 17,500 shares of company stock valued at $1,251,929 over the last ninety days. Corporate insiders own 8.70% of the company’s stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Featured Story: What does cost of debt say about a company’s financial health?

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.